ArticleJournal of immunology (Baltimore, Md. : 1950)2008
A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration.
Article in Journal of immunology (Baltimore, Md. : 1950), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Adenovirus Type 6: Subtle Structural Distinctions from Adenovirus Type 5 Result in Essential Differences in Properties and Perspectives for Gene Therapy.Pharmaceutics · 2021Review
- Respiratory FimA-Specific Secretory IgA Antibodies Upregulated by DC-Targeting Nasal Double DNA Adjuvant Are Essential for Elimination ofFrontiers in immunology · 2021Article
- Adipose-Derived Mesenchymal Stem Cells Restore Impaired Mucosal Immune Responses in Aged Mice.PloS one · 2016Article
- Phenotype and function of nasal dendritic cells.Mucosal immunology · 2015Article
- Innate endogenous adjuvants prime to desirable immune responses via mucosal routes.Protein & cell · 2015Review
- Mucosal Immunosenescence in the Gastrointestinal Tract: A Mini-Review.Gerontology · 2015Review
- Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.Pharmaceutics · 2014Article
- Enhancement of serum and mucosal immune responses to a Haemophilus influenzae Type B vaccine by intranasal delivery.Clinical and vaccine immunology : CVI · 2013Article
- Article
- Novel vaccine development strategies for inducing mucosal immunity.Expert review of vaccines · 2012Review
- A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging.Vaccine · 2012Article
- TLR2-dependent modulation of dendritic cells by LT-IIa-B5, a novel mucosal adjuvant derived from a type II heat-labile enterotoxin.Journal of leukocyte biology · 2011Article
- The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia.Infection and immunity · 2011Article
- Nasal immunity to staphylococcal toxic shock is controlled by the nasopharynx-associated lymphoid tissue.Clinical and vaccine immunology : CVI · 2011Article
- Development of adenoviral vector-based mucosal vaccine against influenza.Journal of molecular medicine (Berlin, Germany) · 2011Review
- Cytokines: the future of intranasal vaccine adjuvants.Clinical & developmental immunology · 2011Review
- Oral-nasopharyngeal dendritic cells mediate T cell-independent IgA class switching on B-1 B cells.PloS one · 2011Article
- New insights on adenovirus as vaccine vectors.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Review
- A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity.Vaccine · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
Abstract
Previously, we showed that nasal administration of a naked cDNA plasmid expressing Flt3 ligand (FL) cDNA (pFL) enhanced CD4(+) Th2-type, cytokine-mediated mucosal immunity and increased lymphoid-type dendritic cell (DC) numbers. In this study, we investigated whether targeting nasopharyngeal-associated lymphoreticular tissue (NALT) DCs by a different delivery mode of FL, i.e., an adenovirus (Ad) serotype 5 vector expressing FL (Ad-FL), would provide Ag-specific humoral and cell-mediated mucosal immunity. Nasal immunization of mice with OVA plus Ad-FL as mucosal adjuvant elicited high levels of OVA-specific Ab responses in external secretions and plasma as well as significant levels of OVA-specific CD4(+) T cell proliferative responses and OVA-induced IFN-gamma and IL-4 production in NALT, cervical lymph nodes, and spleen. We also observed higher levels of OVA-specific CTL responses in the spleen and cervical lymph nodes of mice given nasal OVA plus Ad-FL than in mice receiving OVA plus control Ad. Notably, the number of CD11b(+)CD11c(+) DCs expressing high levels of costimulatory molecules was preferentially increased. These DCs migrated from the NALT to mucosal effector lymphoid tissues. Taken together, these results suggest that the use of Ad-FL as a nasal adjuvant preferentially induces mature-type NALT CD11b(+)CD11c(+) DCs that migrate to effector sites for subsequent CD4(+) Th1- and Th2-type cytokine-mediated, Ag-specific Ab and CTL responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.